CranioSense develops IPASS, a non-invasive technology for measuring intracranial pressure (ICP) using a forehead patch and handheld device. This system provides rapid ICP readings without the risks associated with traditional invasive cranial monitoring. The technology enables timely ICP assessment for traumatic brain injury patients outside of critical care settings.
Funding
$130K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Following a traumatic brain injury (TBI), elevated intracranial pressure (ICP) can lead to serious health issues, including brain damage, coma, or even death. However, current methods for measuring ICP are invasive, expensive, and risky, involving drilling a hole in the skull and inserting a sensor into the brain. As a result, the vast majority of TBI patients do not have their ICP tested, leaving them vulnerable to severe complications.
Solution
CranioSense has developed the IPASS Intracranial Pressure Assessment and Screening System, a non-invasive technology that measures ICP in seconds. IPASS utilizes a forehead patch, two clip-on sensors, and a handheld device to provide rapid ICP assessment without the need for invasive procedures. This easy-to-use system aims to address the critical issue of under-testing for ICP in TBI patients, enabling timely intervention and potentially preventing serious health consequences.
Target Audience
The primary target audience includes medical professionals involved in the care of TBI patients, such as neurointensivists, paramedics, and hospital staff.
Features
- Non-invasive ICP measurement using a forehead patch and clip-on sensors
- Rapid assessment of ICP in seconds
- Handheld device for easy operation and data display